Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 46 Lymphoma, Large B-Cell, Diffuse 26 Precursor Cell Lymphoblastic Leukemia-Lymphoma 23 Leukemia, Myeloid, Acute 20 Lung Neoplasms 19 Burkitt Lymphoma 18 Recurrence 14 Lymphoma 14 Hodgkin Disease 14 Lymphoma, Non-Hodgkin 13 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10 Neuroblastoma 10 Lymphoma, Mantle-Cell 10 Lymphoma, B-Cell 10 Leukemia 10 Carcinoma, Non-Small-Cell Lung 10 Medulloblastoma 8 Neoplasms, Germ Cell and Embryonal 7 Neoplasms 7 Lymphoma, Follicular 7 Multiple Myeloma 6 Lymphoma, T-Cell 6 Brain Neoplasms 6 Sarcoma, Ewing 5 Retinoblastoma 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Immunoblastic Lymphadenopathy 5 Ependymoma 5 Rhabdomyosarcoma 4 Rhabdoid Tumor 4

Interventions

Etoposide 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Extensive Small Cell Lung Cancer × Etoposide × 1 year × Clear all

NCT07083375 2025-07-24

QL1706

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting

Extensive Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡